Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Einstein College receives grant to develop stem cell-based therapies

Scientists at Albert Einstein College of Medicine of Yeshiva University have received a five-year, $10.8 million grant to develop stem cell-based therapies that could be used to mitigate radiation-induced gastrointestinal syndrome - part of acute radiation syndrome (ARS) - for military personnel, first responders and the general public. The Einstein research, funded by the federal Centers for Medical Countermeasures Against Radiation, is part of a program coordinated by the National Institute of Allergy and Infectious Diseases.

12 Aug 2010

NMDP applauds introduction of 'Stem Cell Therapeutic and Research Reauthorization Act of 2010'

The National Marrow Donor Program today applauded the introduction of the "Stem Cell Therapeutic and Research Reauthorization Act of 2010." Sens. Orrin Hatch (R-UT), Christopher Dodd (D-CT), Richard Burr (R-NC), Jack Reed (D-RI), John Ensign (R-NV), and Al Franken (D-MN) introduced the act in the U.S. Senate as S. 3751 on Thursday, Aug. 5. Last evening, Reps. C.W. Bill Young (R-FL) and Doris Matsui (D-CA) introduced the companion legislation, (H.R. 6081), in the House.

11 Aug 2010

USPTO allows Regulus Therapeutics' claims of key Tuschl III patent covering Mir-155

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office has allowed claims in a patent application (US Serial No. 12/550,579) derived from the "Tuschl III" patent series. The allowed claims relate to human microRNA miR-155, a microRNA that is a potential target for immuno-inflammatory indications, and a lead program of the Regulus-GSK Strategic Alliance.

11 Aug 2010

Two NJIT biomedical researchers receive Coulter Foundation Translational Awards for patent application

Two NJIT biomedical researchers have received the prestigious Coulter Foundation Translational Awards for promising patent applications that may some day extend peoples' lives.The Coulter program provides funding for professors in established biomedical engineering departments within the U.S. Initial funding for each professor will be at least $200,000 over a two-year period.

11 Aug 2010

Cord Blood America to begin sale of DNA Predisposition testing services

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that within 90 days it will begin selling DNA Predisposition testing services in conjunction with The DNA Shop, LLC,Henderson, Nevada.

11 Aug 2010

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

Genmab A/S announced today top-line interim results from an initial Phase II single arm open label study of ofatumumab to evaluate the treatment of relapsed Diffuse Large B-Cell Lymphoma in patients ineligible for or relapsed following a stem cell transplant.

11 Aug 2010

StemCells second-quarter net loss decreases to $4.61 million

StemCells, Inc., a leading stem cell company developing and commercializing novel stem cell therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results and business highlights for the second quarter ended June 30, 2010.

11 Aug 2010

FDA approves human embryonic stem cells clinical trial for spinal cord injury treatment

Emerging Healthcare Solutions, Inc.: Last week, the US Food and Drug Administration gave their highly-anticipated approval for the first clinical trial using human embryonic stem cells (hESCs), which are the type of cells that can develop into all tissues of the body. Geron Corporation of Menlo Park, California, received the green light from the US FDA to use cells derived from hESCs to treat people with acute spinal cord injuries. Ten people will receive injections into the injury site of hESC-derived oligodendrocyte progenitor cells, which stimulate the growth of new and severed nerves and recoat damaged nerves with myelin. The hope is that the injections will help people recover function lost through injury, as seen in rodent studies in 2005.

10 Aug 2010

New scaffold supports growth, integration of stem cell-derived cardiac muscle cells

These days people usually don't die from a heart attack. But the damage to heart muscle is irreversible, and most patients eventually succumb to congestive heart failure, the most common cause of death in developed countries.Stem cells now offer hope for achieving what the body can't do: mending broken hearts. Engineers and physicians at the University of Washington have built a scaffold that supports the growth and integration of stem cell-derived cardiac muscle cells. A description of the scaffold, which supports the growth of cardiac cells in the lab and encourages blood vessel growth in living animals, is published this week in the Proceedings of the National Academy of Sciences.

10 Aug 2010

Research on role of ADAM12 gene in breast cancer

A microscopic gene may play a gigantic role when it comes to cancerous tissue in the human body, according to one Kansas State University research team.The team is investigating mutation within the ADAM12 gene of the A Disintegrin and Metalloprotease family, or ADAM family, and its role in breast cancer."We want to know whether ADAM12 is a good guy or a bad guy in breast cancer," said Anna Zolkiewska, associate professor of biochemistry and research team leader.

10 Aug 2010

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Pluristem Therapeutics Inc. today announced the results of two separate pre-clinical studies in animal models which demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for both neuropathic and inflammatory nerve pain. These animal studies were conducted in collaboration with the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and the Department of Anesthesiology and Operative Intensive Care Medicine, both at the Charité-Universitätsmedizin of Berlin, Germany.

10 Aug 2010

Duke University physicists develop technique to inject material into cells through sharp fluid jets

Duke University physicists have developed a way to produce sharp fluid jets with enough precision that they can inject material into a single, living cell. The technique promises a way to deliver drugs to cells one at a time, which is likely to be very valuable for research involving stem cells and other cellular-level studies. The research appears in the current issue of the APS journal Physical Review Letters.

10 Aug 2010

Athersys second-quarter revenues increase to $1.9 million

Athersys, Inc. today announced its financial results for the quarter ended June 30, 2010.

10 Aug 2010

RNL BIO research identifies adult stem cell's ability to inhibit cancer

The leading biopharmaceutical company specialized in adult stem cell therapeutics, RNL BIO Co., Ltd, announced on July 27th that adult stem cell was identified to have cancer suppressive activity in a preclinical study.

10 Aug 2010

New familial link in juvenile myelomonocytic leukemia discovered

A UCSF-led team has discovered a direct link between an inherited genetic mutation, a set of developmental abnormalities and a rare form of childhood leukemia called juvenile myelomonocytic leukemia, or JMML. The study demonstrates a new familial link in JMML and has significant implications, the researchers say, for improving the diagnosis and treatment of the disease.

9 Aug 2010

Shlomo Melmed appointed to Independent Citizen's Oversight Committee

Shlomo Melmed, M.D., senior vice president for academic affairs and dean of the medical faculty at Cedars-Sinai Medical Center, has been appointed by Gov. Arnold Schwarzenegger to the Independent Citizen's Oversight Committee, the governing board of the California Institute for Regenerative Medicine.

7 Aug 2010

Osiris Therapeutics reports second-quarter net income of $1.7M against loss last year

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, cardiovascular and orthopedic areas, announced today its results for the second quarter of fiscal 2010.

7 Aug 2010

UCSF researchers discover new technology purifying special types of stem cells

UCSF researchers are reporting the first success in very rapidly purifying one type of embryonic stem cell from a mix of many different types of embryonic stem cells in the culture dish. The technique, which avoids the need to genetically alter the cells to distinguish them, is a key advance, the researchers say, for obtaining the appropriate cells for repairing specific damaged tissues.

7 Aug 2010

UC Riverside scientists secure grants for tobacco control research

Tobacco-related disease kills more people worldwide than any other single factor. To help address this problem, the University of California, Riverside has received six grants from the University of California Tobacco-Related Disease Research Program (TRDRP), the most TRDRP grants the campus has received in any year.

6 Aug 2010

Salamander research findings bring scientists closer to future regenerative therapies

Tissue regeneration in salamanders and newts seems like it should be the stuff of science fiction. But it happens routinely. Why can't we mammals just re-grow a limb or churn out a few new heart muscle cells as needed? New research suggests there might be a very good reason: Restricting our cells' ability to pop in and out of the cell cycle at will - a prerequisite for the cell division necessary to make new tissue - reduces the chances that they'll run amok and form potentially deadly cancers.

6 Aug 2010

Stem Cells News and Research

Further Reading

Einstein College receives grant to develop stem cell-based therapies

NMDP applauds introduction of 'Stem Cell Therapeutic and Research Reauthorization Act of 2010'

USPTO allows Regulus Therapeutics' claims of key Tuschl III patent covering Mir-155

Two NJIT biomedical researchers receive Coulter Foundation Translational Awards for patent application

Cord Blood America to begin sale of DNA Predisposition testing services

Genmab reports top-line interim results from ofatumumab Phase II study in Diffuse Large B-Cell Lymphoma

StemCells second-quarter net loss decreases to $4.61 million

FDA approves human embryonic stem cells clinical trial for spinal cord injury treatment

New scaffold supports growth, integration of stem cell-derived cardiac muscle cells

Research on role of ADAM12 gene in breast cancer

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Duke University physicists develop technique to inject material into cells through sharp fluid jets

Athersys second-quarter revenues increase to $1.9 million

RNL BIO research identifies adult stem cell's ability to inhibit cancer

New familial link in juvenile myelomonocytic leukemia discovered

Shlomo Melmed appointed to Independent Citizen's Oversight Committee

Osiris Therapeutics reports second-quarter net income of $1.7M against loss last year

UCSF researchers discover new technology purifying special types of stem cells

UC Riverside scientists secure grants for tobacco control research

Salamander research findings bring scientists closer to future regenerative therapies

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo